Spherix, Fullife Healthcare sign supply and license agreement Spherix Incorporated and Fullife Healthcare announced the signing of a supply and license agreement for the use of D-tagatose in nutraceutical products in India. Under the terms of the agreement, Spherix has granted Fullife an exclusive, royalty-bearing license in India for use of Spherix's clinical data and proprietary know-how to support marketing and dosing of the D-tagatose that Spherix will also be supplying. The D-tagatose will be used in food or cosmetic products that may provide health benefits in return for a fixed royalty on gross sales. Spherix will provide bulk D-Tagatose to Fullife and Fullife will be responsible for all testing and development of products containing D-Tagatose for sale in India. Financial terms of the agreement were not disclosed.
News For SPEX From The Last 14 Days
Check below for free stories on SPEX the last two weeks.